A sin­gle in­jec­tion of Uni­ty's an­ti-ag­ing hy­poth­e­sis bears fruit in PhII, as piv­otal plans shape up

We all know the scene. Jamie Lee Cur­tis’ char­ac­ter in “Freaky Fri­day” pens a book ti­tled “Through the Look­ing Glass: Senes­cence in Ret­ro­grade,” and she goes on a talk show to pro­mote the work, but it’s not her do­ing the talk­ing — her daugh­ter, played by Lind­say Lo­han, has swapped bod­ies with her and the two must fig­ure out how to re­verse the odd turn of events.

Senes­cent cells have been at the heart of Uni­ty Biotech­nol­o­gy for years, as the biotech has gone through the drug R&D hur­dles try­ing to prove out its an­ti-ag­ing hy­poth­e­sis. On Tues­day, Uni­ty has like­ly found a light at the end of the tun­nel: a piv­otal study of its on­ly clin­i­cal-stage drug is now on tap for Sep­tem­ber 2023 af­ter a Phase II tri­al in di­a­bet­ic mac­u­lar ede­ma proved to be durable out to 24 weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER